# K081641

# 510(k) Summary COULTER速 LIN-X Linearity Controls

# 10 Submitted By:

Nancy Nadler   
Staff Regulatory Affairs Specialist   
Beckman Coulter, Inc   
11800 S W 147 Avenue   
M/S 31-B06   
Miami, Florda 33196-2500   
Telephone (305) 380-4191   
FAX (305) 380-3618

# Date Submitted:

June 6, 2008

0

# Device Name(s):

# 3 1 Proprietary Names

COULTER速 LIN-X LinearIty Control

# 32 Classification Name

Hematology quality control mixture (21 CFR $\ S$ 864 8625)

# 40 Predicate Device:

<table><tr><td>Candidate(s)</td><td>Predicate</td><td>Manufacturer</td><td>Docket Number</td></tr><tr><td rowspan="2">COULTER@ LIN-X Linearity Control</td><td>COULTER@ LIN-C Linearity Control (Cleared as COULTER Linearity Controls)</td><td>Beckman Coulter, Inc</td><td rowspan="2">K955334 and K061064</td></tr><tr><td>CBC-Line Hematology Linearity Kit (for calbration assessment only)</td><td>R&amp;D Systems K942822</td></tr></table>

COULTER LIN-X linearity controls are stabilized human blood components whose WBC, RBC, HGB, and PLT concentrations span the instrument's reportable range Results from repeated measurements for each concentration are compared to the established expected range to assess the instrument's calibration and verify the reportable range

# 60 Intended Use:

COULTER LIN-X linearity controls are intended to assess calbration and verify the reportable range of COULTER cellular analysis systems listed in the TABLE OF EXPECTED RESULTS in conjunction with specific COULTER reagents Refer to your Product Manuals or On-line Help System

# 70 Comparison to Predicate(s):

COULTER LIN-X linearty controls are essentially identical to the current COULTER LIN-C linearity controls with the exception of an additional level covering an extended cellular component range, the analyzers on which it may be used and an expanded intended use for calibration assessment

# 8 0 Summary of Performance Data:

Stability, calibration assessment, value assignment and range determination studies were conducted and demonstrate acceptable performance per manufacturing specifications The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equrvalence to products already in commercial distribution

This summary of safety and effectiveness is being submitted in accordance with the requrements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807 92

# JAN 1 6 2009

Beckman Coulter, Inc c/o Ms Nancy Nadler Staff Regulatory Affairs Specialist 11800 SW $1 4 7 ^ { \circ }$ Avenue Miam, FL 33196

Re k081641 Trade/Device Name Coulter $\otimes$ LIN-X Linearty Control Regulation Number 21 CFR 864 8625 Regulation Name Hematology Quality Control Mixture Regulatory Class Class II Product Code JPK Dated January 05, 2009 Recerved January 06, 2009

Dear Ms Nadler

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not requre approval of a premarket approval applcation (PMA) You may, therefore, market the device, subject to the general controls provisions of the Act The general controls provisions of the Act include requrements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration

If your device s classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls Existing major regulations affecting your device can be in  1, Code f Federal Regulatons (CFR), Parts 800 to 895In adion, FDA y publish further announcements concerning your device in the Federal Register

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device comples with other requirements of the Act or any Federal statutes and regulations adminustered by other Federal agencies You must comply with all the Act's requrements, including, but not lmited to registration and listing (21 CFR Part 807), labeling (21 CFR Parts 801 and 809), and good manufacturing practice requirements as set forth in the qualty systems (QS) regulaton (21 CFR Part 820) This letter will allow you to begin marketing your device as descrbed in your Section 510(k) premarket notification The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450 Also, please note the regulation entitled, "Misbranding by reference to premarket notfication" (21CFR Part 807 97) For questions regarding postmarket surveillance, please contact CDRH's Office of Survellance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474 For questons regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Survellance Systems at (240) 276-3464 You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http //www fda gov/cdrh/ndustry/support/ndex html

Sincerely yours,mane M chan

Maria M Chan, Ph D   
Acting Division Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation   
and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use

510k Number( know)08104

Dv NamCOULTER速 LIN-X Lnearty ool

Indications For Use COULTER LIN-X linearity controls are intended to assess calibration and verify the reportable range of COULTER cellular analysis systems listed in the TABLE OF EXPECTED RESULTS in conjunction with specific COULTER reagents Refer to your Product Manuals or On-line Help System

![](images/ec50d07d5f09af0952759ae47964d9ee38a465ac48c08b8355143403c5fdf47a.jpg)  
Page I of 1

# Office of In Vitro Diagnostic Device Evaluation and Safety

# COULTER速 LIN-X Linearity Controls Traditional 5 10(k) Notification

![](images/1fb23966fcced4004523c2fc176a821fc6d1e72dde05bbe9e142408d5b3e469f.jpg)  
Page 14